Advertisement

European Journal of Nuclear Medicine

, Volume 22, Issue 4, pp 356–360 | Cite as

Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain

  • Jyrki T. Kuikka
  • Kim A. Bergström
  • Aapo Ahonen
  • Jukka Hiltunen
  • Jarmo Haukka
  • Esko Länsimiese
  • Shaoyin Wang
  • John L. Neumeyer
Short communication

Abstract

Several cocaine congeners are of potential for imaging the dopamine transporter (DAT). Previous studies have shown that iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane ([123I]β-CIT) is a promising radiotracer for imaging the serotonin (5-HT) and dopamine (DA) transporters in the living human brain with single-photon emission tomography (SPET). [123I]β-CIT was found to be not very practical for 1-day DAT imaging protocols since peak DAT uptake occurs later than 8 h. Here we report a pilot comparison of [123I]β-CIT and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane ([123I]β-CIT FP), using SPET imaging in four healthy male subjects. Peak uptake of [123I]β-CIT-FP into the basal ganglia occurred earlier (3–4 h after injection of tracer) than that of [123I]β-CIT (>8 h). However, the specific DAT binding of [123I]β-CIT-FP in the basal ganglia was somewhat less (0.813±0.047) than that of [123I]β-CIT (0.922±0.004). Imaging quality is excellent with both tracers and they are potentially of value for brain imaging in various neuropsychiatric disorders.

Key words

Dopamine transporter Single-photon emission tomography 2β-Carbomethoxy-3β-(4-iodophenyl)tropane 2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Innis RB, Baldwin RM, Sybirska E, et al. Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [123I]CIT.Eur J Pharmacol 1991; 200: 369–370.PubMedGoogle Scholar
  2. 2.
    Kuikka JT, Bergström KA, Vanninen E, et al. Initial experience with SPET examinations using [123I]-2β-carbomethoxy-3β(4-iodophenyl) tropane in human brain.Eur J Nucl Med 1993; 20: 783–786.PubMedGoogle Scholar
  3. 3.
    Brücke T, Kornhuber J, Angelberger P, et al. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT. Binding kinetics in the human brain.J Neural Transm [Gen Sect] 1993; 94: 137–146.Google Scholar
  4. 4.
    Innis R, Seibyl J, Wallace E, et al. SPECT imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease.Proc Natl Acad Sci USA 1993; 90: 11965–11969.PubMedGoogle Scholar
  5. 5.
    Farde L, Halldin C, Müller L, Suhari T, Karlsson P, Hall H. PET study of [11C]β-CIT binding to monoamine transporters in the monkey and human brain.Synapse 1994; 16: 93–103.PubMedGoogle Scholar
  6. 6.
    Neumeyer JL, Wang S, Gao Y, et al.N-ω-Fluoroalkyl analogues of (1R)-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters.J Med Chem 1994; 37: 1558–1561.PubMedGoogle Scholar
  7. 7.
    Baldwin RM, Zea-Ponce Y, Al-Tikriti MS, et al. Regional brain uptake and pharmacokinetics of [123I]N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl)nortropane esters in baboons.Nucl Med Biol 1994; (in press).Google Scholar
  8. 8.
    Costa DC, Verhoeff NPLG, Cullum ID, et al. In vivo characterization of 3-iodo-6-methoxybenzamide [123I] in humans.Eur J Nucl Med 1990; 16: 813–816.PubMedGoogle Scholar
  9. 9.
    Kuikka JT, Bergström KA, Ahonen A, Länsimies E. The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β(4-iodophenyl) tropane.Eur J Nucl Med 1994; 21: 53–56.PubMedGoogle Scholar
  10. 10.
    Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporters in healthy human subjects.J Cereb Blood Flow Metab 1994: 14; 982–994.PubMedGoogle Scholar
  11. 11.
    Bergström KA, Halldin C, Kuikka JT, et al. Lipophilic metabolite of [123I]β-CIT in human plasma may obstruct quantitation of the dopamine transporter.Synapse (in press).Google Scholar
  12. 12.
    Innis RB. Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease.Eur J Nucl Med 1994; 21: 1–5.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Jyrki T. Kuikka
    • 1
  • Kim A. Bergström
    • 1
  • Aapo Ahonen
    • 2
  • Jukka Hiltunen
    • 3
  • Jarmo Haukka
    • 3
  • Esko Länsimiese
    • 1
  • Shaoyin Wang
    • 4
  • John L. Neumeyer
    • 4
  1. 1.Department of Clinical PhysiologyKuopio University HospitalKuopioFinland
  2. 2.Department of Clinical ChemistryOulu University Central HospitalOuluFinland
  3. 3.MAP Medical Technologies OyTikkakoskiFinland
  4. 4.Research Biochemicals International (RBI)NatickUSA

Personalised recommendations